AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AAPG · NASDAQ · Biotechnology

Ascentage Pharma (ADR) (AAPG)

Develops and commercializes hematology therapies in China and global clinical trials.

$15.51

vs last close−0.36 (−2.27%)

In millions of USD, except per-share figures · converted from CNY at the latest rate

In millions	Q4 FY20Dec 2020	Q2 FY21Jun 2021	Q4 FY21Dec 2021	Q2 FY22Jun 2022	Q4 FY22Dec 2022	Q2 FY23Jun 2023	Q4 FY23Dec 2023	Q2 FY24Jun 2024	Q4 FY24Dec 2024	Q2 FY25Jun 2025	Q4 FY25Dec 2025	Q2 FY26Jun 2026
Revenue	1	0	0	16	16	21	12	123	23	35	50	45
Cost of revenue	0	0	0	2	2	3	2	2	2	3	10	7
Gross profit	1	2	2	14	14	19	10	121	21	32	40	37
	50	67	67	77	77	69	89	93	106	114	135	148
Research & development	42	57	57	55	55	46	59	66	75	79	88	101
	5	14	14	24	24	26	30	26	31	35	48	47
Selling & marketing	0	4	4	12	12	12	17	13	16	21	0	0
General & administrative	5	11	11	13	13	14	13	13	15	15	0	0
Other expenses	3	−5	−5	−3	−3	−3	0	0	0	0	0	0
Operating income	−50	−65	−65	−63	−63	−51	−79	28	−85	−83	−96	−111
	−1	3	3	−3	−3	−9	0	−4	1	−5	0	−8
Interest income	0	1	1	1	1	5	0	0	0	1	7	5
Interest expense	0	1	1	4	4	11	3	4	0	0	4	4
Other non-operating income	0	−4	−4	−1	−1	−5	0	0	0	0	0	0
Income before tax	−50	−62	−62	−66	−66	−60	−80	24	−83	−87	−95	−119
Income tax expense	0	−4	−4	0	0	0	−1	0	2	1	0	2
Net income from continuing operations	−51	−58	−58	−66	−66	−60	−78	24	−85	−88	−96	−121
Other adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Net income	−51	−58	−58	−66	−66	−60	−78	24	−85	−88	−96	−121
EPS, basic	−$3.75	−$3.67	−$3.67	−$4.00	−$4.00	−$6.76	−$1.07	$0.33	−$1.09	−$1.03	−$1.03	−$1.30
EPS, diluted	−$3.75	−$3.67	−$3.67	−$4.00	−$4.00	−$6.76	−$1.07	$0.33	−$1.09	−$1.03	−$1.03	−$1.30
Weighted average shares, basic	13	16	16	16	16	18	73	74	78	85	93	93
Weighted average shares, diluted	13	16	16	16	16	18	73	74	78	85	93	93
EBITDA	−50	−61	−61	−62	−62	−37	−74	34	−79	−77	−89	−105
Depreciation & amortization	0	0	0	1	1	8	6	6	6	6	6	6
EBIT	−50	−61	−61	−62	−62	−45	−79	28	−85	−83	−96	−111